Gilead Sciences Inc. (NASDAQ: GILD) released its first-quarter financial results after the markets closed on Tuesday.
The company said that it had $1.48 in earnings per share (EPS) on $5.09 billion in revenue. Consensus estimates from Thomson Reuters had called for $1.67 in EPS on revenue of $5.4 billion. The same period of last year reportedly had EPS of $1.63 and $5.34 billion in revenue.
During the quarter, product sales were $3.5 billion in the United States, $1.0 billion in Europe and $469 million in other locations. Antiviral product sales, a subset that includes sales of HIV, chronic hepatitis B (HBV) and chronic hepatitis C (HCV) products, totaled $4.4 billion for the quarter:
- HIV and HBV product sales were $3,329 million for the first quarter of 2018 compared to $3,265 million for the same period in 2017. The increase was primarily due to the continued uptake of tenofovir alafenamide (TAF)-based products, which include Genvoya, Descovy and Odefsey.
- HCV product sales, which consist of Epclusa, Harvoni, Vosevi and Sovaldi, were $1,046 million for the first quarter of 2018 compared to $2,576 million for the same period in 2017. The decline was primarily due to lower sales of Harvoni and Sovaldi across all major markets and lower sales of Epclusa in the United States as a result of increased competition.
Also in this quarter, the board of directors declared a cash dividend of $0.57 per share of common stock for the second quarter of 2018. The dividend is payable on June 28 to stockholders of record at the close of business on June 15.
Looking ahead to the 2018 full year, the company expects to see revenues in the range of $20.0 billion to $21.0 billion and gross margin in the range of 85% to 87%. The consensus estimates call for $6.47 in EPS on $21.29 billion in revenue for the full year.
On the books, Gilead’s cash, cash equivalents and marketable securities totaled $32.1 billion at the end of the quarter, down from $36.7 billion at the end of the previous fiscal year.
Shares of Gilead closed Tuesday at $72.56, with a consensus analyst price target of $89.05 and a 52-week range of $63.76 to $89.54. Following the announcement, the stock was down nearly 6% at $68.32 in early trading indications Wednesday.
24/7 Wall St.Credit card companies are handing out rewards and benefits to win the best customers. A good cash back card can be worth thousands of dollars a year in free money, not to mention other perks like travel, insurance, and access to fancy lounges. See our top picks for the best credit cards today. You won’t want to miss some of these offers.
Flywheel Publishing has partnered with CardRatings for our coverage of credit card products. Flywheel Publishing and CardRatings may receive a commission from card issuers.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
